eedq has been researched along with medetomidine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takano, Y; Yaksh, TL | 1 |
| Durcan, MJ; Linnoila, M; Morgan, PF; Van Etten, ML | 1 |
2 other study(ies) available for eedq and medetomidine
| Article | Year |
|---|---|
Relative efficacy of spinal alpha-2 agonists, dexmedetomidine, clonidine and ST-91, determined in vivo by using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible antagonist.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Clonidine; Dose-Response Relationship, Drug; Imidazoles; Injections, Spinal; Male; Medetomidine; Morphine; Quinolines; Rats; Rats, Inbred Strains; Receptors, Adrenergic, alpha; Spinal Cord | 1991 |
Covariation of alpha 2-adrenoceptor density and function following irreversible antagonism with EEDQ.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Body Temperature; Dioxanes; Drug Interactions; Exploratory Behavior; Hypnotics and Sedatives; Idazoxan; Imidazoles; Male; Medetomidine; Mice; Motor Activity; Quinolines; Radioligand Assay; Receptors, Adrenergic, alpha-2 | 1994 |